A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Bedford PK, South Australia 5042, Australia
Salzburg, 5020, Austria
Wuhan, Hubei 430030, China
Nanjing, Jiangsu 210008, China
Hangzhou, Zhejiang 310003, China
Ningbo, Zhejiang 315000, China
PierreBenite, 69495, France
Poitiers, 86000, France
Kurashikishi, Okayama-ken 710-8602, Japan
Osakashi, Osaka 543-8555, Japan
Chuoku, Tokyo 104-0045, Japan
Gdask, 80-219, Poland
Saint Petersburg, Sankt-Peterburg 191024, Russia
Edirne, 22030, Turkey (Türkiye)
Lviv, 79044, Ukraine